Royalty Report: Drugs, Medical, Cell Line – Collection: 363077

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Medical
  • Cell Line
  • Drug Discovery
  • Biotechnology
  • Cancer
  • cell therapy
  • Supply
  • Test/Monitoring
  • Assay
  • Disease
  • Device
  • Therapeutic
  • Stem cells

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 363077

License Grant
Licensor hereby grants to United Kingdom Licensee a sole and exclusive (even as to Licensor), royalty-bearing, worldwide license under the Licensor Patent Rights to research, develop, make, have made, use, have used, sell, have sold, offer for sale and import Licensee Products in the Licensee Transplantation Field.

Licensor hereby grants to Licensee a sole and exclusive (even as to Licensor), royalty-bearing, worldwide license under the Licensor Patent Rights to make and use c-MycER Cells to research, develop, make, have made, use, have used, sell, have sold, offer for sale and import Licensee NCTs in the Licensee Discovery Field.

Licensor hereby grants to Licensee a non-exclusive, royalty-bearing, worldwide license, under the Licensor Patent Rights to research, develop, make, have made, use, have used, sell, have sold, offer for sale and import, Unregulated Cells in the Licensee Reagent Field.

License Property
c-MycER Cells shall mean human neural Stem Cells and Progenitor Cells conditionally immortalized with the c-Myc oncogene with an estrogen response element under tamoxifen control. c-MycER Cells shall not include human neural Stem Cells or Progenitor Cells or their progeny or derivatives that are not conditionally immortalized with c-myc under the control of the estrogen response element.

Stem Cell shall mean an undifferentiated Cell capable of proliferation, self maintenance and the production of a large number of differentiated functional progeny.

Progenitor Cell shall mean an undifferentiated Cell capable of limited proliferation and the production of differentiated functional progeny.

Cell Line shall mean c-MycER Cells of clonal origin, differentiated by the integration site of the c-MycER Cell insert.

Cells shall mean cultures of neural Stem Cells to the full extent described or claimed in the Licensor Patent Rights and shall include all progeny and derivatives of such stem cells (including Progenitor Cells and their progeny and Stem Cells and their progeny) and “Cell” shall mean one of such cells.

Licensee NCT shall mean a non-cellular therapeutic molecule, i.e., a new chemical or biological molecule, identified or developed by Licensee through the practice of inventions claimed in or covered by one or more of the Licensor Patents or molecules derived therefrom, which identification or development occurred during the term of a Valid Claim of any such Licensor Patent.

Licensor Patent Rights shall mean
(a) the patents and patent applications (the Licensor Patents),
(b) any and all United States or foreign patents and patent applications corresponding to any of the foregoing patents and patent applications, whether now existing of hereafter filed,
(c) any provisionals, substitutions, divisionals, reissues, renewals, continuations, continuations-in-part (but only to the extent not directed to new matter), extensions (including patent term extensions), substitute applications and inventors’ certificates arising from, or based upon, any of the foregoing patents or patent applications, in respect of the foregoing;
(d) any patents issuing from any of the foregoing patent applications; and
(e) any issued patents now or hereafter owned or Controlled by Licensor or an Affiliate of Licensor to the extent necessary or useful for the manufacture, use or sale of
(i) a c-MycER Cell (including without limitation a product utilizing a c-Myc-ER Cell) identified or developed, in whole or in part, through the practice by Licensee or a sub-licensee of Licensee of inventions claimed in or covered by one or more of the Licensor Patents, or
(ii) a Licensee NCT.

Licensee Product shall mean a c-MycER Cell or a product utilizing a c-MycER Cell identified or developed, in whole or in part, through the practice by Licensee or a sub-licensee of Licensee of inventions claimed in or covered by one or more of the Licensor Patents, which practice occurred during the term of a Valid Claim of any such Licensor Patent.

Field of Use
Licensee Transplantation Field shall mean Transplantation of c-MycER Cells for the diagnosis, prevention and treatment of human diseases other than those in the Licensor Field.

Licensee Discovery Field shall mean use of c-MycER Cells for the research, discovery, screening and development of new non-cellular therapeutics for use in the treatment of any disease state or condition in humans.

Licensee Reagents Field shall mean use of Unregulated Cells for research and other non-clinical and non-therapeutic purposes (not including administration to humans).

IPSCIO Record ID: 367267

License Grant
United Kingdom Licensor hereby grants to Licensee a sole and exclusive (even as to Licensor), royalty-bearing, worldwide license under the Licensor Patent Rights and Licensor c-MycER Cell Technology, to research, develop, make, have made, use, have used, sell, have sold, and offer for sale Licensee Products in the Licensee Field and to use the c-MycER Cells in order to make, use or sell an Licensee Product in the Licensee Field. Any sub-licenses included in any of the foregoing licenses under Licensor Patent Rights are granted subject to the applicable terms and conditions of the agreement.
License Property
c-MycER Cells shall mean human neural Stem Cells and Progenitor Cells conditionally immortalized with the c-Myc oncogene with an estrogen response element under tamoxifen control. c-MycER Cells shall not include human neural Stem Cells or Progenitor Cells or their progeny or derivatives that are not conditionally immortalized with c-myc under the control of the estrogen response element.

Stem Cell shall mean an undifferentiated Cell capable of proliferation, self maintenance and the production of a large number of differentiated functional progeny.

Progenitor Cell shall mean an undifferentiated Cell capable of limited proliferation and the production of differentiated functional progeny.

Cell Line shall mean c-MycER Cells of clonal origin, differentiated by the integration site of the c-MycER Cell insert.

Cells shall mean cultures of neural Stem Cells to the full extent described or claimed in the Licensee Patent Rights and shall include all progeny and derivatives of such stem cells (including Progenitor Cells and their progeny and Stem Cells and their progeny) and “Cell” shall mean one of such cells.

Licensor c-MycER Cell Technology shall mean all know-how, data, biological materials, inventions and other proprietary information and technology owned or Controlled by Licensor and relating to the manufacture, sale, use or manipulation of c-MycER Cells.

Licensor Patent Rights shall mean
(a) the patents and patent applications (the Licensor Patents),
(b) any and all United States or foreign patents and patent applications corresponding to any of the foregoing patents and patent applications, whether now existing of hereafter filed,
(c) any provisionals, substitutions, divisionals, reissues, renewals, continuations, continuations-in-part (but only to the extent not directed to new matter), extensions (including patent term extensions), substitute applications and inventors’ certificates arising from, or based upon, any of the foregoing patents or patent applications, in respect of the foregoing;
(d) any patents issuing from any of the foregoing patent applications, and
(e) any issued patents now or hereafter owned or Controlled by Licensor or an Affiliate of Licensor to the extent necessary or useful for the manufacture, use or sale of any product or method utilizing c-MycER Cells or Licensor c-MycER Cell Technology in the Licensee Field.

Licensee Product shall mean any product or method utilizing c-MycER Cells, the manufacture, use, or sale of which, but for the license granted to Licensee hereunder, would infringe any Valid Claim of the Licensor Patent Rights.

Field of Use
Licensee Field shall mean the diagnosis, prevention and treatment of (i) lysosomal storage diseases, (ii) spinal cord injury, or (iii) myelin-affected disorders including, without limitation, cerebral palsy and multiple sclerosis.

IPSCIO Record ID: 802

License Grant
Subject to Canadian Licensor's right to acquire a co-exclusive interest as provided in this Agreement, Licensor grants to the Company an exclusive, royalty-bearing, worldwide license, with the right to grant sublicenses to the Company Sublicensees, under the Cell Technology and Patent Rights to make, have made, use, have used, sell, have sold, and manipulate Products in the Field and to perform the Services in the Field.
License Property
Cell Technology shall mean all know-how, data, biological materials, inventions and other proprietary information and technology relating to the manufacture, sale, use or manipulation of Cells within the Field provided to the Company prior to the Effective Date.

Cells shall mean in vitro generated, growth factor responsive neural stem cells to the extent claimed in the Patent Rights and shall include all progeny and derivatives of such stem cells (including Progenitor Cells and their progeny and Stem Cells and their progeny) and Cell shall mean one of such cells. An in vitro generated growth factor responsive neural stem cell shall include a neural stem cell, or its derivatives or progeny, which exhibits one or more of the following characteristics

(a) is dependent on the presence of a growth factor for survival and viability, or (b) proliferates or differentiates due to the presence of a growth factor, whether alone or in combination with another biologically active molecule; and

An EGF-responsive neuronal stem cell includes
a neuronal stem cell, or its derivatives or progeny, which exhibits one or more of the following characteristics

(a) is dependent on the presence of EGF for survival and viability, or (b) proliferates or differentiates due to the presence of EGF, whether alone or in combination with another biologically active molecule all to the extent claimed or allowed under the Patent Rights.

Product shall mean any product utilizing the Cells and the manufacture, use, or sale of which, but for the license granted to the Company hereunder, would infringe any claim of the Patent
Rights.

Services shall mean any use of the Cells or the Cell Technology to perform a service for a third party for compensation, where such use would, but for the license granted to the Company hereunder, infringe any claim of the Patent Rights.

Field of Use
Field shall mean the use of Cells for Transplantation only, including, without limitation

(a) for Cell Replacement Therapy; (b) for the purposes of Transplantation anywhere in the human body for the treatment or prevention of human disease, injury, or disorder; (c) for augmenting the function of endogenous cells by Transplantation or Cell Replacement Therapy; and (d) for the purposes of transplantation therapy in general (e.g., Transplantation of the Cells for delivery of one or more Agents).

IPSCIO Record ID: 286075

License Grant
Licensor, government research agency, grants to Licensee, subject to the terms and conditions herein, an exclusive license in the Licensed Territory under the Licensed Patents to make, have made, use, have used, sell and have sold Licensed Products for the term of this Agreement.

Licensor grants to Licensee, subject to the terms and conditions herein, an exclusive license in the Licensed Territory to make, have made, use, have used, sell and have sold Licensed Materials for the term of this Agreement.

Licensor grants to Licensee the right to grant sublicenses subject to the provisions of this Agreement and to the prior submission to and approval by Licensor of the proposed sublicense, which approval shall not be unreasonably withheld.

License Property
Licensed Patents means U.S. Patent No. 5,532,156, entitled “Hepatocyte Cell Line Derived From the Epiblast of Pig Blastocysts”, which issued on July 2, 1996, all reissues, reexaminations, and patent term extensions of this patent; U.S. Patent No. 5,866,420, entitled “Artificial Liver Device”, which issued on February 2, 1999, all reissues, reexaminations and patent term extensions of this patent; and any U.S. Patent Applications and resulting issued patents encompassed by ARS Invention Disclosure Docket No. 0024.05 entitled 'ARS-PICM-19H Fetal Pig Hepatocyte Cell Line', all continuations, divisions, reissues, reexaminations, patent term extensions of such patents, any continuations-in-part that have complied with the requirements set forth in 37 CFR 404.7 and any foreign equivalents thereof.

5,532,156 – Hepatocyte cell line derived from the epiblast of pig blastocysts
5,866,420 – Artificial liver device

Licensed Products I means any and all in vitro toxicological testing platforms for determining the potential toxicity and metabolism of new pharmacological compounds in the liver using the Licensed Materials and/or the isolated cell line of normal pluripotent parenchymal hepatocytes derived from a primary culture of pig epiblast cells as encompassed by the claims of the Licensed Patents.

Licensed Products II means any bioartifical liver device for use in human patients as encompassed by the claims of the Licensed Patents or which directly incorporates the Licensed Materials.

Licensed Materials means any and all of the fetal pig hepatocyte cell line(s) described in the Licensed Patents, including, but not limited to “ARS-PICM-19” and “ARS-PICM-19H”, and all progeny, subclones and modified and/ or unmodified derivatives thereof.

Field of Use
The license agreement is for the liver cell line for the use of patented liver cell lines in artificial liver devices

IPSCIO Record ID: 7349

License Grant
The Licensee entered into a royalty Agreement with the Licensor and received the following assets from the Licensor
License Property
Certain patents and patent applications and all related active prosecution cases, trade secrets, know-how and certain other intellectual property rights, and all of the Licensor's goodwill with respect to the technology directly related to the research, development and commercialization of certain products and know-how related to hES cells;

Certain biological materials and reagents (including master and working cell banks, original and seed banks, and research, pilot and GMP grade lots and finished product);

Certain regulatory filings for clinical trials for GRNOPC-I for spinal cord injury, including the investigational new drug applications filed with the United States Food and Drug Administration for Licensor’s Phase I safety study of oligodendrocyte progenitor (GRNOPC-1) cells in patients with neurologically complete, subacute spinal cord injury (Protocol No. CP35A007), and long term follow up of subjects who received GRNOPC1 (Protocol No. CP35A008), and the clinical trial for VAC1 for acute myelogenous leukemia, including a Phase I/II study of active immunotherapy with GRNVAC1, autologous mature dendritic cells transfected with mRNA encoding human telomerase reverse transcriptase (hTERT), in patients with acute myelogenous leukemia (AML) in complete remission (Protocol No. CP06-151).

US Patent 6,800,480 – Methods and Materials for the Growth of Primate-Derived Primordial Stem Cells in Feeder-Free Culture
US Patent 7,413,902 – Feeder-Free Culture Method for Embryonic Stem Cells
US Patent 6,440,735 – Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer
US Patent 7,402,307 – Method for Identifying and Killing Cancer Cells
US Patent 7,824,849 – Cellular Telomerase Vaccine and Its Use for Treating Cancer
US Patent 7,560,281 – Use of TGF Beta Superfamily Antagonists to Make Dopaminergic Neurons from Embryonic Stem Cells
US Patent 8,252,586 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent 8,153,428 – Use of TGF Beta Superfamily Antagonists and Neurotrophins to Make Neurons from Embryonic Stem Cells
US Patent 6,667,176 – cDNA Libraries Reflecting Gene Expression During Growth and Differentiation of Human Pluripotent Stem Cells
US Patent 7,041,438 – Use of Human Embryonic Stem Cells for Drug Screening and Toxicity Testing
US Patent 7,413,904 – Embryonic Stem Cells Having Genetic Modifications
US Patent 7,410,798 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 7,297,539 – Medium for Growing Human Embryonic Stem Cells
US Patent 7,455,983 – Medium for Growing Human Embryonic Stem Cells
US Patent 8,097,458 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent 6,642,048 – Conditioned Media for Propagating Human Pluripotent Stem Cells
US Patent 6,458,589 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 6,506,574 – Hepatocyte Lineage Cells Derived from Pluripotent Stem Cells
US Patent 7,256,042 – Process for Making Hepatocytes from Pluripotent Stem Cells
US Patent 7,282,366 – Hepatocytes for Therapy and Drug Screening Made From Embryonic Stem Cells
US Patent 7,473,555 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent 8,148,151 – Differentiation of Primate Pluripotent Cells to Hepatocyte-Lineage Cells
US Patent 6,833,269 – Making Neural Cells for Human Therapy or Drug Screening from Human Embryonic Stem Cells
US Patent 8,148,148 – Neural Progenitor Cell Populations
US Patent 8,252,585 – Neural Progenitor Cell Populations
US Patent 7,250,294 – Screening Small Molecule Drugs Using Neural Cells Differentiated from Human Embryonic Stem Cells
US Patent 7,763,463 – Use of Cyclic AMP and Ascorbic Acid to Produce Dopaminergic Neurons from Embryonic Stem Cells
US Patent 6,576,464 – Differentiated Cells Suitable For Human Therapy
US Patent 6,921,665 – Selective Antibody Targeting of Undifferentiated Stem Cells
US Patent 7,732,199 – Process for Making Transplantable Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,763,464 – Differentiation Protocol for Making Human Cardiomyocytes
US Patent 7,452,718 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,897,389 – Direct Differentiation Method for Making Cardiomyocytes from Human Embryonic Stem Cells
US Patent 7,851,167 – Differentiation Protocol for Making Human Cardiomyocytes

US Patent Application 13/561,296 – Neural Cell Populations from Primate Pluripotent Stem Cells
US Patent Application 12/170,219 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 12/710,078 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 13/323,567 – Culture System for Rapid Expansion of Human Embryonic Stem Cells
US Patent Application 11/917,993 – Suspension Culture of Human Embryonic Stem Cells
US Patent Application 12/277,136 – Protocols for Making Hepatocytes from Embryonic Stem Cells
US Patent Application 13/558,078 – Neural Progenitor Cell Populations
US Patent Application 11/359,341 – Differentiated Cells Suitable For Human Therapy
US Patent Application 11/471,916 – Differentiation of Primate Pluripotent Stem Cells to Cardiomyocyte-Lineage Cells

Field of Use
The Licensee is a biotechnology company focused on the emerging field of regenerative medicine, with core technologies centered on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency.

IPSCIO Record ID: 286096

License Grant
Whereas, the University, has waived its interest to certain parts of the Technology, inter alia, the multipotent postnatal derived progenitor cells, and that waived part of the Technology, which is now Licensee Company Technology is assigned to and owned by the Licensee; and
Whereas, the remaining part of the Technology, known as the University Technology, is owned by the University and ownership of the Licensee Technology and the University Technology is governed by a separate agreement between the University and the Licensee,
The University is granting to the Licensee an exclusive license to the University Technology.

The University grants an irrevocable, exclusive right and license in any and all Fields of Use, including the right to sub license to Affiliates or unrelated third parties, to the Licensed Patents and the University Technology to make, have made, use, sell, offer to sell, import and export, lease or otherwise dispose of Licensed Product in the Territory.

License Property
The University developed Technology relating to multipotent postnatal derived progenitor cells, their precursors, progeny and components, products made therefrom, processes used in their production and processing, and methods for their use.

The technology shall mean Licensees Technology and University Technology, including but not limited to, multipotent postnatal derived progenitor cells, precursors, progeny or components thereof, products and information obtained from the foregoing, processes and products utilized in production or processing of any of the foregoing, methods of utilizing any of the foregoing, and any Trade Secret Information or know-how relating to the foregoing. The term Technology shall also include any invention involving multipotent postnatal derived progenitor cells (a) that is the result of research conducted.

Licensed Patent shall mean a Patent that claims as an invention one or more aspects of the Technology.

Licensed Product shall mean any Technology which is within the scope of one or more claims of a Licensed Patent and, but for the license granted in this Agreement, would infringe, constitute contributory infringement, or constitute inducement to infringe of one or more such claims when made by, made for, used, sold, offered for sale, imported, exported, leased, or otherwise disposed of by the Licensee.

Field of Use
The Field of Use shall mean any and all fields of use, including but not limited to diagnostic, therapeutic and research applications.

Lysosomal storage disorders are a group of more than 40 recessive genetic diseases resulting in deficiencies in lysosomal acid hydrolases. Although individually rare, lysosomal storage disorders have a prevalence of 1 per 7700 live births. Such diseases include Gaucher's disease, Fabry disease, Niemann-Pick disease, mucopolysaccharidoses Type I through VII, Tay-Sachs disease, among many others. Loss of lysosomal enzyme activity results in the progressive accumulation of undegraded substrate within the lysosomes, resulting in engorgement of the organelle, subsequent cellular, tissue, and organ dysfunction, and often death. Lysosomal storage diseases affect multiple organ systems, many of them before birth, resulting in irreversible defects. Clinical treatments for metabolic storage disorders are limited to bone marrow transplantation and enzyme replacement therapy.

IPSCIO Record ID: 291121

License Grant
University grants to Licensee a worldwide, exclusive license with the right by Licensee to grant sublicenses, under the Patent Rights to make, have made, use, sell, offer for sale and import Licensed Products. Licensee will not grant any sublicense under Patent Rights unless it first receives the prior written consent of  University, which consent will not be unreasonably withheld. University shall retain the right to make and use Licensed Products in its own laboratories for scientific purposes and for continued research  provided that such Licensed Products are not sold by University.
License Property
University is the owner of U.S. and foreign patent applications relating to (l) the proliferation of hepatocyte precursors and (2) hepatoblasts and methods of isolating same.

Patent Rights means the United States and foreign patent applications, including any divisionals, continuations and continuations-in-part, and any patents issuing thereon, including any substitutions, extensions, reissues, reexaminations, and inventors certificates.

Licensed Product means any product, the manufacture, use or sale of which is covered by a claim of Patent Rights.

Field of Use
Patents relates to research conducted on liver stem and precursor cells.  A hepatocyte is a cell of the main parenchymal tissue of the liver.

IPSCIO Record ID: 274909

License Grant
Licensor grants to the Licensee of the United Kingdom, and its Affiliates, an exclusive license under Licensor Background Patent Rights, Licensor Future Patent Rights, Licensor Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights, and Licensor Know-How to develop, have developed, make, have made, use, sell, have sold, and import Cellular Assay Products throughout the Territory in the Cellular Assay Products Field.

Licensor grants
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights, Licensor’s interest in Joint Alliance IP Rights and Licensor Know-How to develop, make, use, sell, have sold, and import products throughout the relevant territories in the Limited Field and,
—  a non-exclusive, irrevocable license under Licensor’s Alliance IP Rights and Licensor’s interest in Joint Alliance IP Rights to develop, have developed, make, have made, use, sell, have sold, and import products throughout the relevant territories in the Limited Field.

Licensor grants an option to negotiate in good faith and on commercially reasonable terms
—  an exclusive, payable license, with the right to sublicense for the Limited Field under Licensor Alliance IP Rights, and Licensor’s interest in Joint Alliance IP Rights, and;
—  a sub-license for the Cellular Assay Products Field in the Territory.

License Property
The patents and know-how are for certain intellectual property rights related to the propagation and differentiation of human embryonic derived cells.
Field of Use
The Cellular Assay Products Field shall mean the use of Cellular Assay Products for in vitro assay applications, including but not limited to drug discovery and development, drug monitoring, drug toxicology testing, and consumer products testing, but excluding the use of any Cellular Assay Product in any therapeutic or diagnostic application.

The Licensor Field shall mean therapies that comprise, or are derived from, or developed or manufactured using, human embryonic stem cells.

The Limited Field shall mean products or services that contain cells that comprise, or are derived from, or manufactured using, human embryonic stem cells (and not human induced pluripotent stem cells) in markets outside of the Licensor Field and the Cellular Assay Products Field.

Cellular assay products derived from human embryonic stem cells (hESCs) is for use in drug discovery, development and toxicity screening.

IPSCIO Record ID: 289180

License Grant
Licensor, a medical college, hereby grants to Licensee and its Affiliates a worldwide exclusive license of Licensors entire interest under Licensed Patent Rights, Licensed Know-how and Licensed Materials to make, have made, use and sell (including to sell for resale by others) Licensed Product(s).

Licensor hereby grants to Licensee under Licensed Patent Rights, Licensed Know-how and Licensed Materials the exclusive right to grant one or more non-exclusive sub-licenses to make, have made, use and sell Licensed Product(s) provided only that such sub-licenses are granted by Licensee to such sub-licensees on terms no less favorable to Licensor than provided for herein.

License Property
Licensed Patent Rights, as used herein, shall mean U.S. Patent Application Serial No. 08/151,065 and any other patent applications or patents covering Licensed Materials.  The term Licensed Patent Rights shall include any divisions, continuations, continuation-in-part or reissues, and all foreign counterparts thereof, covering Licensed Materials.

Licensed Materials, as used herein, shall mean cell lines that inducibly express adeno-associated virus (AAV) proteins developed by James P. Trempe, Ph.D., Biochemistry & Molecular Biology, MCO (hereinafter referred to as Investigator), and improvements made by Investigator to such cell lines which exist as of the date of execution of this Agreement or are conceived of and reduced to practice by Investigator during the five (5) year period beginning on the effective date of this Agreement and are owned by Licensor.

Licensed Product(s), as used herein, shall mean any composition of matter, product, apparatus, kit or component part thereof, and any process, procedure or method which cannot be developed, manufactured, used or sold without utilizing Licensed Rights.

Field of Use
This agreement pertains to the medical industry relating to Cell Lines.

IPSCIO Record ID: 85354

License Grant
A research institute grants an exclusive license in the territory under the patent rights and property rights, with the right to grant sublicenses, to use the biological materials and to make, use, sell, offer for sale and import licensed products.
License Property
The patent rights are for United States patent application 14/508,763, any U.S. or foreign patent or patent application that is a divisional, continuation, reissue, renewal, reexamination, substitution or extension of at least one of the patents and patent applications identified.
Field of Use
This license is for all fields of use.  Licensee is a development stage enterprise and intends to complete the testing of its erectile dysfunction (ED) treatment and, if warranted, market treatment kits to physicians for use with their patients suffering from ED.  This license agreement pertains to the medical industry.

IPSCIO Record ID: 383612

License Grant
Licensor grants an exclusive, even as to Licensor, except as required for Licensor to meet its development and supply obligations hereunder, right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property and Licensors interest in any Joint Patent Rights and Joint Technology solely to research, develop, make, have made, use, sell, offer for sale and import Products in the Field in the Licensee Territory, and a non-exclusive right and license, with the right to sublicense, during the Term of this Agreement under the Licensor Intellectual Property to research, make, have made, use and export Products in the Field in North America.
License Property
Licensor is a stem cell therapeutic leader focused on developing and marketing products to treat medical conditions and possesses broad scientific and clinical leadership in the field of human mesenchymal stem cells (MSCs) and know-how, expertise and intellectual property rights pertaining to MSCs, including its Prochymal product and Chondrogen product.

Chondrogen shall mean any formulation, dosage form or delivery system that contains culturally expanded, undifferentiated, unmodified human MSCs for local delivery for the Articulating Orthopedic Indication and any Improvements thereto.

Prochymal shall mean any formulation, dosage form or delivery system suitable for Vascular Administration that contains culturally expanded, undifferentiated, unmodified human MSCs, and any Improvements thereto.

Ulcerative Colitis Indication shall mean the use of Prochymal for the treatment or prevention of ulcerative colitis.

Mesenchymal Stem Cells or MSCs shall mean the human formative pluripotential blast cells found inter alia in bone marrow, blood, dermis and periosteum that are capable of differentiating into any of the specific types of mesenchymal or connective tissues.

COPD Indication shall mean the use of Prochymal to treat chronic obstructive pulmonary disease.

Articulating Orthopedic Indication shall mean the use of Chondrogen for preventing or treating diseases, defects or conditions of articulating joints, including cartilage and meniscus repair, osteoarthritis, osteochondral defect repair, and the treatment of acute and chronic orthopedic pain within an articulating joint.

Crohns Indication shall mean the use of Prochymal to treat Crohns disease.

Diabetes Indication shall mean the use of Prochymal for the prevention or treatment of Type I diabetes.

GvHD Indication shall mean the use of Prochymal to treat or prevent graft versus host disease.

Cardiac Indication shall mean the use of Prochymal to treat or prevent acute myocardial infarction.

Pain Therapeutic shall mean use of Chondrogen for the mitigation or relief of orthopedic pain with a Statistically Significant duration of relief of at least one year.

Field of Use
Field shall mean with respect to Prochymal, all applications for the prevention or treatment of diseases, defects, or conditions in humans, and with respect to Chondrogen, the Articulating Orthopedic Indication.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.